Linda Munson, DO
Psychiatry · Valparaiso, INNPI 1477542561
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 427 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$861
- AbbVie$717
- Lundbeck LLC$602
- Neurocrine Biosciences, Inc.$581
- Alkermes, Inc.$556
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,94496%
- Education$2614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 87 | $1,631 |
| Otsuka America Pharmaceutical, Inc. | 61 | $861 |
| AbbVie(2 entities) | 54 | $717 |
| Lundbeck LLC | 38 | $602 |
| Neurocrine Biosciences, Inc. | 30 | $581 |
| Alkermes, Inc. | 40 | $556 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $530 |
| Johnson & Johnson | 28 | $455 |
| Vanda Pharmaceuticals Inc. | 17 | $444 |
| Orexo US, Inc. | 10 | $200 |
| Axsome Therapeutics, Inc. | 6 | $116 |
| Eisai Inc. | 5 | $83 |
| Supernus Pharmaceuticals, Inc. | 2 | $76 |
| Indivior Inc. | 5 | $75 |
| Noven Therapeutics, LLC | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Corium, LLC | 2 | $24 |
| Almatica Pharma LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
How this compares
$7,205 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 25 | $212,574 |
| RexultiBrexpiprazole | 37 | $54,350 |
| Invega SustennaPaliperidone Palmitate | 16 | $31,207 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 202 | $30,539 |
| VraylarCariprazine Hcl | 18 | $23,577 |
| Paliperidone ErPaliperidone | 19 | $16,360 |
| Lurasidone Hcl | 38 | $13,957 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $9,145 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $5,837 |
| Aripiprazole | 67 | $5,434 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $2,838 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 62 | $2,377 |
| Bupropion Hcl SrBupropion Hcl | 83 | $2,104 |
| Chlorpromazine Hcl | 12 | $1,976 |
| Vilazodone Hcl | 25 | $1,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $581 | $212,57425 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $861 | $54,35037 claims |
| Johnson & JohnsonInvega Sustenna | $455 | $31,20716 claims |
| AbbVieVraylar | $717 | $23,57718 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $66 | $9,14522 claims |
| Orexo US, Inc.Zubsolv | $200 | $5,83713 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $87390 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Valparaiso
- Samir GuptaValparaiso$6K
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Christopher BojrabCarmel$713K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Louis CadyNewburgh$135K
- Charles BeasleyIndianapolis$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.